BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1639232)

  • 1. Ebrotidine effect on the proteolytic and lipolytic activities of Helicobacter pylori.
    Slomiany BL; Piotrowski J; Mojtahed H; Slomiany A
    Gen Pharmacol; 1992 Mar; 23(2):203-6. PubMed ID: 1639232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulglycotide effect on the proteolytic and lipolytic activities of Helicobacter pylori toward gastric mucus.
    Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A; Slomiany BL
    Am J Gastroenterol; 1994 Feb; 89(2):232-6. PubMed ID: 8304309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sucralfate on the degradation of human gastric mucus by Helicobacter pylori protease and lipases.
    Slomiany BL; Piotrowski J; Slomiany A
    Am J Gastroenterol; 1992 May; 87(5):595-9. PubMed ID: 1595646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of growth factors to degradation by Helicobacter pylori protease: effect of ebrotidine and sucralfate.
    Slomiany BL; Piotrowski J; Slomiany A
    Biochem Mol Biol Int; 1996 Sep; 40(1):209-15. PubMed ID: 8886287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Helicobacter pylori urease activity by ebrotidine.
    Piotrowski J; Slomiany A; Slomiany BL
    Biochem Mol Biol Int; 1995 Oct; 37(2):247-53. PubMed ID: 8673007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helicobacter pylori aggregating activity of gastric mucin with ulcer healing by ebrotidine.
    Piotrowski J; Majka J; Piotrowski E; Murty VL; Gabryelewicz A; Slomiany A; Slomiany BL
    Biochem Mol Biol Int; 1994 Nov; 34(5):875-81. PubMed ID: 7535617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of gastric mucosal mucin receptor by H. pylori lipopolysaccharide: effect of ebrotidine.
    Slomiany BL; Piotrowski J; Murty VL; Slomiany A
    Gen Pharmacol; 1995 Nov; 26(7):1553-8. PubMed ID: 8690245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide.
    Slomiany BL; Piotrowski J; Slomiany A
    J Physiol Pharmacol; 1999 Sep; 50(3):391-404. PubMed ID: 10574469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement in the protective qualities of gastric mucus with combination therapy of ebrotidine and amoxicillin for H. pylori eradication.
    Slomiany BL; Piotrowski J; Slomiany A; Konturek JW; Domschke WW
    Gen Pharmacol; 1998 Aug; 31(2):227-31. PubMed ID: 9688464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement in the protective qualities of gastric mucus by ebrotidine during duodenal ulcer healing.
    Slomiany BL; Piotrowski J; Majka J; Czajkowski A; Slomiany A; Gabryelewicz A
    Gen Pharmacol; 1995 Sep; 26(5):1039-44. PubMed ID: 7557247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of gastric somatostatin receptor inhibition by Helicobacter pylori lipopolysaccharide with ebrotidine and sulglycotide.
    Piotrowski J; Skrodzka D; Slomiany A; Slomiany BL
    Gen Pharmacol; 1997 May; 28(5):705-8. PubMed ID: 9184806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ebrotidine on the synthesis and secretion of gastric sulfomucin.
    Slomiany BL; Lopez RA; Liau YH; Slomiany A
    Gen Pharmacol; 1993 May; 24(3):611-7. PubMed ID: 8365641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide: effect of ebrotidine.
    Piotrowski J; Morita M; Slomiany A; Slomiany BL
    Biochem Int; 1992 Jun; 27(1):131-8. PubMed ID: 1385705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ebrotidine.
    Patel SS; Wilde MI
    Drugs; 1996 Jun; 51(6):974-80; discussion 981. PubMed ID: 8736619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and secretion of gastric sulfomucin in the presence of ebrotidine, a new antiulcer agent.
    Slomiany BL; Lopez RA; Slomiany A
    Biochem Int; 1992 Dec; 28(4):665-74. PubMed ID: 1482403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastroprotective agents in mucosal defense against Helicobacter pylori.
    Slomiany BL; Murty VL; Piotrowski J; Slomiany A
    Gen Pharmacol; 1994 Sep; 25(5):833-41. PubMed ID: 7835626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of gastric mucus phospholipid secretion by an antiulcer agent, ebrotidine.
    Slomiany BL; Piotrowski E; Piotrowski J; Zirvi KA; Liau YH; Murty VL; Slomiany A
    Gen Pharmacol; 1994 Sep; 25(5):1033-7. PubMed ID: 7835621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori.
    Alarcón T; Domingo D; Sánchez I; Sanz JC; Martínez MJ; López-Brea M
    Eur J Clin Microbiol Infect Dis; 1998 Apr; 17(4):275-7. PubMed ID: 9707312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastroprotective properties of ebrotidine. A review.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.